- Report
- January 2025
Bahrain
From €1365EUR$1,500USD£1,175GBP
- Report
- January 2025
Austria
From €1365EUR$1,500USD£1,175GBP
- Report
- January 2025
Australia
From €1365EUR$1,500USD£1,175GBP
- Report
- January 2025
Argentina
From €1365EUR$1,500USD£1,175GBP
- Report
- January 2025
Albania
From €1365EUR$1,500USD£1,175GBP
- Report
- March 2024
Czech Republic
From €1365EUR$1,500USD£1,175GBP
The Factor VIII market is a segment of the hematological drugs market, which includes drugs used to treat blood-related disorders. Factor VIII is a protein that helps blood to clot, and is used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Factor VIII is typically administered intravenously, and is available in both recombinant and plasma-derived forms.
The Factor VIII market is highly competitive, with a number of companies offering products. These include Novo Nordisk, Pfizer, Bayer, CSL Behring, and Shire. Additionally, there are several smaller companies that offer Factor VIII products, such as Octapharma, Kedrion, and Biotest. Show Less Read more